Diagnostic Products Corp. Primes Pipeline For Imminent AIP Revocation
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic Products Corp. (DPC) expects a series of U.S. product approvals by year-end, pending the removal of an application integrity policy, according to CEO Michael Ziering